N-acetylation in healthy and diseased children

Area of Science:

• Pharmacogenetics
• Pediatric Metabolism
• Drug Metabolism

Background:

• Acetylation capacity, a key metabolic process, varies among individuals.
• Understanding acetylation phenotypes in pediatric populations is crucial for drug efficacy and safety.
• Previous studies have suggested potential links between acetylation status and certain childhood diseases.

Purpose of the Study:

• To investigate and compare the acetylation capacity in healthy Czech children, children with phenylketonuria (PKU), and children with insulin-dependent diabetes mellitus (IDDM).
• To determine the prevalence of fast and slow acetylator phenotypes in these pediatric groups.
• To explore potential associations between acetylation capacity and PKU or IDDM.

Main Methods:

• A sulfamethazine oral test dose (20 mg/kg) was administered to 82 healthy children (4-15 years), 41 children with PKU (3-15 years), and 48 children with IDDM (5-15 years).
• Plasma and urine concentrations of sulfamethazine and its acetylated metabolite were measured 6 hours post-dose.
• Acetylation indices were calculated to classify individuals as fast or slow acetylators.

Main Results:

• Healthy children: 39% fast acetylators; no significant gender or age differences.
• Children with PKU: Significantly higher proportion of fast acetylators (58.5% by plasma, 70.7% by urine); inverted slow/fast acetylator ratio compared to controls.
• Children with IDDM: 39.6% fast acetylators, similar to healthy children, not supporting a fast acetylator phenotype association with Type I diabetes.

Conclusions:

• Children with phenylketonuria exhibit significantly enhanced acetylation capacity compared to healthy controls.
• The fast acetylator phenotype is not associated with Type I diabetes in the pediatric population.
• Acetylation capacity assessment provides valuable insights into metabolic differences in pediatric diseases.